中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners



Lingmed Newsletter Nov 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:Innovative Acute Myeloid Leukemia New Drug Program
  • Lingmed asset recommendation 2: Novel Interfering Peptide for Topical Acne Treatment
  • Lingmed monthly webinar Dec 2022: Global microbiome-based drug development status and trends   Register now
  • The Oct 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Oct 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team


Lingmed asset recommendation No.313

Innovative Acute Myeloid Leukemia New Drug Program seeks Global Partner - LMP1472

  • Global & Chinese Acute Myeloid Leukemia Epidemiology
  • Global Acute Myeloid Leukemia Drug Ranking
  • Guidelines for the Treatment of Acute Myeloid Leukemia in China
  • Lingmed innovative asset recommendation – Acute Myeloid Leukemia Program - LMP1472


Lingmed asset recommendation No.312

Novel Interfering Peptide Project for Topical Acne Treatment seeks Cooperation- LMP1589

  • Global & Chinese Acne Epidemiology
  • Global Acne Drug Ranking
  • Guidelines for Acne Treatment in China (2019)
  • Lingmed innovative asset recommendation – Acne Program


Lingmed Newsletter Oct 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:Sjögren's Syndrome Dry Eye Project from EU
  • Lingmed asset recommendation 2: Overseas Psoriasis Project
  • Lingmed monthly webinar Nov 2022: Neoantigen—— A New Breakthrough in Tumor Immunotherapy   Register now
  • The Sep 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Sep 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team


Lingmed asset recommendation No.310

Psoriasis Program seeks Chinese Partner- LMP1559

  • Global & Chinese Epidemiology of Psoriasis
  • Global Psoriasis Drug Ranking
  • Guidelines for the Treatment of Psoriasis in China
  • Lingmed innovative asset recommendation – Psoriasis program-LMP1559


Lingmed asset recommendation No.309

European Sjögren's Syndrome Dry Eye Project seeks Global Collaboration

  • Global & Chinese Sjögren’s Syndrome Dry Eye Epidemiology
  • Global Sjögren's Syndrome Drug Ranking
  • Guidelines for the treatment of dry eye with Sjögren's syndrome in China
  • Lingmed innovative asset recommendation – Sjögren's Syndrome Dry Eye Program- LMP1640


Lingmed Newsletter Sep 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:Overseas neurodegenerative disease project
  • Lingmed asset recommendation 2: IBD project with innovative mechanism from US
  • Lingmed monthly webinar Oct 2022: Innovative biotech road shows   Register now
  • The Aug 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Aug 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team


Lingmed asset recommendation No.307

U.S Innovation Mechanism IBD Program seeks Chinese Partner - LMP1553

  • Global & Chinese Inflammatory Bowel Disease Epidemiology
  • Global Inflammatory Bowel's Disease Drug Ranking
  • Guidelines for the Treatment of Inflammatory Bowel disease in China
  • Lingmed innovative asset recommendation – Inflammatory bowel disease program


Lingmed asset recommendation No.306

Neurodegenerative Disease Program seeks Chinese Partner-LMP1593

  • Global and Chinese Alzheimer's Disease Epidemiology
  • Global and Chinese Alzheimer's Disease Drug Ranking
  • Guidelines for the Treatment of Alzheimer's disease in China
  • Lingmed innovative asset recommendation – Alzheimer's disease program-LMP1593


Lingmed Newsletter August 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:High potential autoimmune disease project from US
  • Lingmed asset recommendation 2: Dermatology project with innovative mechanism from US
  • Lingmed monthly webinar Sep 2022: Technical challenges of exosome drug carrier development
  • The July 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The July 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team


Lingmed asset recommendation No.304

U.S. Innovative Mechanisms' Dermatology Program seeks Chinese Partner- LMP1487

  • Global & Chinese Rosacea Epidemiology
  • Global and Chinese Rosacea Drug Ranking
  • Guidelines for the Treatment of Rosacea in China (2021)
  • Lingmed innovative asset recommendation – Rosacea medication -LMP1487




If you are interested in Lingmed historical achieved reports, please click here





Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

©Copyright 2013 - 2022 Lingmed Limited